Overview
Adipotide is a synthetic peptide analog designed to target white adipose tissue. It consists of a targeting moiety that binds to prohibitin, a protein found on blood vessels supplying white adipose tissue, linked to a pro-apoptotic peptide. This targeted approach aims to reduce fat mass by selectively destroying the blood supply to fat cells, leading to their apoptosis.
The development of Adipotide was based on the premise that directly targeting the vasculature of white adipose tissue could offer a more effective and less systemic approach to weight loss compared to traditional methods. Initial research focused on preclinical models to assess its efficacy and safety.
Mechanism of Action
Adipotide's mechanism of action involves two primary steps. First, the peptide selectively binds to prohibitin, a protein expressed on the surface of endothelial cells within the blood vessels of white adipose tissue. This binding ensures targeted delivery of the pro-apoptotic peptide to the desired location.
Once bound, the pro-apoptotic portion of Adipotide triggers apoptosis (programmed cell death) in the targeted endothelial cells. This leads to the destruction of the blood vessels supplying the fat cells, effectively cutting off their nutrient supply. As a result, the fat cells undergo apoptosis, leading to a reduction in overall fat mass.
Key Benefits
- Potential for targeted fat mass reduction
- May improve metabolic parameters associated with obesity
Research & Indications
Preclinical studies in obese rodents and non-human primates have demonstrated significant weight loss and improvements in insulin resistance following Adipotide administration. These studies showed a reduction in white adipose tissue mass and associated metabolic benefits.
It is important to note that Adipotide is currently not approved for human use and remains an investigational compound. Clinical trials are needed to evaluate its safety and efficacy in humans. Research is ongoing.
Dosing Protocols
Disclaimer: Dosing protocols are provided for informational purposes only and do not constitute medical advice. Consult with a qualified healthcare professional before using Adipotide.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weight Loss | 0.04 - 0.08 mg/kg of body weight | Daily | SubQ |
Supplies Needed
For an 8-16 week protocol:
- Peptide Vials: Sufficient quantity of Adipotide to complete the cycle, based on individual dosing.
- Insulin Syringes (U-100): Quantity depends on injection frequency (daily injections require more). Estimate 5-7 per week.
- Bacteriostatic Water: 10mL bottle for reconstitution.
- Alcohol Swabs: One for vial + one for injection site daily.
Side Effects & Safety
Reported side effects in animal studies include kidney damage, nausea and vomiting. As Adipotide is not approved for human use, the full spectrum of potential side effects in humans is not yet known. Due to the potential for kidney damage, individuals with pre-existing kidney conditions should avoid this peptide.
Storage & Handling
Adipotide should be stored lyophilized (freeze-dried) at -20°C until reconstitution. After reconstitution with bacteriostatic water, it should be stored at 2-8°C and used within a reasonable timeframe (typically within a few weeks, but consult the supplier's recommendations for specific stability data).